

Special Issue

Lipids, Lipoproteins, and Atherothrombotic Disease: Clinical Pharmacology Now and in the Future

Message from the Guest Editors

Despite the success of statin therapy for decreasing the plasma levels of LDL cholesterol, cardiovascular disease and stroke remain major causes of death in developed countries. Although novel and highly effective lipid-lowering therapies such as PCSK9 inhibitors have been developed in recent years, there is an urgent need to develop novel therapies to improve the clinical management of the atherothrombotic disease. Recent studies point to alternative therapeutic targets that could not be only addressed to quantitatively decrease lipid levels in blood but also to improve the function and qualitative characteristics of lipoproteins, thereby decreasing the cardiovascular risk. This Special Issue aims to update the current pharmacological strategies and to present possible new therapeutic targets that have emerged in recent years. We welcome the submission of original research and review articles on novel molecular mechanisms implicated in the development of cardiovascular and atherothrombotic disease, as well as recent advances in drug targets and therapeutic approaches.

Guest Editors

Dr. Jose Luis Sanchez-Quesada

Cardiovascular Biochemistry Group, Biomedical Research Institute IIB Sant Pau, C/Sant Quinti, 77-79, 08041 Barcelona, Spain

Dr. Sonia Benítez González

Institut d'Investigació Biomèdica Sant Pau (IIB Sant Pau), Barceona, Spain

Deadline for manuscript submissions

closed (20 August 2021)



Journal of Clinical Medicine

an Open Access Journal
by MDPI

Impact Factor 2.9
CiteScore 5.2
Indexed in PubMed



mdpi.com/si/51172

Journal of Clinical Medicine
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
jcm@mdpi.com

mdpi.com/journal/

jcm





Journal of Clinical Medicine

an Open Access Journal
by MDPI

Impact Factor 2.9
CiteScore 5.2
Indexed in PubMed



[mdpi.com/journal/
jcm](https://mdpi.com/journal/jcm)



About the Journal

Message from the Editorial Board

There has been an explosion of gene and target based research and therapeutics in the multitude of fields that compose clinical medicine. The *Journal of Clinical Medicine's* (JCM) staff and editorial board are dedicated to providing cutting edge, timely, and peer-reviewed articles covering the diverse subspecialties of clinical medicine. The journal publishes concise, innovative, and exciting research articles as well as clinically significant articles and reviews that are pertinent to the myriad of disciplines within medicine. The articles published are relevant to both primary care physicians and specialists. The journal's full-texts are archived in PubMed Central and indexed in PubMed. Please consider submitting your manuscripts for publication to our journal and check us out on-line!

Editors-in-Chief

Prof. Dr. Emmanuel Andr  s

Internal Medicine Department, University Hospital Strasbourg, 67000
Strasbourg, France

Prof. Dr. Kent Doi

Department of Acute Care Medicine, University of Tokyo, Tokyo, Japan

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Medicine, General and Internal) / CiteScore - Q1
(General Medicine)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17.7 days after submission; acceptance to publication is undertaken in 2.7 days (median values for papers published in this journal in the first half of 2025).